Emergent BioSolutions Inc. (EBS) Stock Price & Analysis
Emergent BioSolutions Inc. (EBS) closed at USD 7.09 on Wednesday, October 28, 2026, up 6.30% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.67; the Oct 28, 2026 session ranged USD 6.56–7.09 on volume of 800,656 shares. Market capitalization is $363.53M, with a 52-week range of USD 4.36–14.06 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 06:30 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EBS.md
Key facts (EBS)
- Last four reported quarters (through Jun 30, 2026): revenue $770M, net income -$177M (-23.0% margin), free cash flow $85.9M (SEC filings).
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $689K; 0 not under a Rule 10b5-1 plan ($0K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (3 analysts), mean target USD 11 (range 10–12).
- Total return with dividends: 1Y -24.6% vs S&P 500 +13.6%; 5Y -85.1% vs S&P 500 +79.8%.
- Next earnings: 2026-11-02, EPS estimate USD -0.39, revenue estimate $123M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EBS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.77B | $1.12B | $1.05B | $1.04B | $743M | $770M |
| Gross profit | $891M | $383M | $318M | $362M | $417M | — |
| Operating income | $341M | -$170M | -$726M | -$109M | $100M | -$66.0M |
| Net income | $220M | -$212M | -$761M | -$191M | $52.6M | -$177M |
| EPS (diluted) | $4.06 | -$4.22 | -$14.85 | -$3.60 | $0.93 | — |
| Free cash flow | $96.1M | -$150M | -$258M | $35.8M | $157M | $85.9M |
| Gross margin | 50.3% | 34.3% | 30.3% | 34.7% | 56.1% | — |
| Operating margin | 19.2% | -15.2% | -69.2% | -10.4% | 13.5% | -8.6% |
| Net margin | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% | -23.0% |
| Revenue growth | +12.4% | -37.0% | -6.1% | -0.5% | -28.8% | — |
| Cash + short-term investments | $576M | $643M | $112M | $99.5M | $205M | — |
| Total debt | $850M | $1.41B | $868M | $700M | $590M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (EBS)
P/S 0.5x · EV/Sales 1.1x · P/FCF 4.2x · P/B 1.1x · FCF yield 23.63% · Earnings yield -48.63% · Buyback yield (TTM) 9.90% · Net debt $450M · EV $814M
P/E at fiscal year-ends: Dec 2025 13.3x.
Insider sales (SEC Form 4, open-market, last ~7 months) (EBS)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Degolyer Donald W | Director | 17,800 | $126K | 13.7% | Yes | Too little history (no open-market trades in 2023) |
| 2026-10-01 | Williams Paul Anthony | SVP, Products Business | 3,000 | $20K | 1.9% | Yes (adopted November 14, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Williams Paul Anthony | SVP, Products Business | 3,000 | $25K | 1.9% | Yes (adopted November 14, 2025) | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Dayal Sujata Tyagi | Director | 13,761 | $116K | 12% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-01 | Degolyer Donald W | Director | 15,481 | $130K | 10.7% | Yes | Too little history (no open-market trades in 2023) |
| 2026-05-01 | Zoon Kathryn C | Director | 17,202 | $144K | 17.7% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-04-30 | Katkin Keith | Director | 15,481 | $128K | 13.9% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (EBS)
Consensus Hold (mean 3.00 on a 1–5 scale), 3 analysts; mean target USD 11 (low 10, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | HC Wainwright & Co. | Reiterated | Buy | $10 |
| 2026-08-10 | HC Wainwright & Co. | Target lowered | Buy | $12 → $10 |
Total return (dividends reinvested) (EBS)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -24.6% | -85.1% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -24.6% | -31.6% |
| Volatility (annualized) | 81.7% | 97.8% |
| Max drawdown | -68.0% (Jan 2026→Aug 2026) | -97.0% (Jan 2022→Feb 2024) |
EBS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.60 | $0.11 | Beat +445.5% | — |
| — | Quarter ended Mar 31, 2026 | $0.21 | −$0.25 | Beat +$0.46 | — |
| — | Quarter ended Dec 31, 2025 | −$0.43 | $0.11 | Miss −$0.54 | — |
| — | Quarter ended Sep 30, 2025 | $1.06 | −$0.12 | Beat +$1.18 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
EBS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 16, 2026 | 8-K | Director or executive officer change, or pay arrangement “On October 16, 2026, Emergent BioSolutions Inc. (the " Company ") announced that Richard Lindahl, the Company's Chief Financial Officer, will step down from his role as the Company's principal financial and accounting officer effective December 31, 2026, after which he will continue as an advisor until his retirement on March 31, 2027. The Company has appointed Frank Vargo, Vice President, Treasurer, to serve as the Company's Interim Chief Financial Officer and principal financial and accounting officer beginning…” |
| Sep 14, 2026 | 8-K | Regulation FD disclosure |
| Sep 1, 2026 | 8-K | Other material event “On August 18, 2026, Emergent BioSolutions Inc. ("Emergent") received a contract modification ("Modification No. 21") of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as "AV7909") valued at $24 million. This modification relates to Emergent's AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority…” |
| Aug 14, 2026 | Schedule 13G | American Century ETF Trust, American Century Investment Management, Inc.: 5.4% of shares, passive 5%+ holder |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 5, 2026 | 8-K | Quarterly results; Exit or restructuring costs (layoffs, closures); Director or executive officer change, or pay arrangement; Regulation FD disclosure “On August 5, 2026, the Company announced an organizational restructuring plan (the "Restructuring Plan") intended to strengthen its long-term financial position in response to changes in its business. These strategic actions will lead to a reduction of the Company's current workforce by approximately 93 employees across all areas of the Company and the elimination of approximately 21 positions that are currently vacant, as well as the closure of wet laboratories in Gaithersburg, Maryland. Decisions regarding the…” |
| Jul 31, 2026 | Schedule 13G/A | Vanguard Capital Management: 4.9% of shares, passive 5%+ holder (amended) |
| Jul 28, 2026 | Schedule 13G/A | BlackRock, Inc.: 9.0% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
EBS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Thermo Fisher (TMO) | “First, contract manufacturers such as Thermo Fisher Scientific, Lonza, and FUJIFILM Biotechnologies, all of which offer end-to-end contract manufacturing services encompassing development, drug substance, and drug product.” |
| Supplier | Lonza | “First, contract manufacturers such as Thermo Fisher Scientific, Lonza, and FUJIFILM Biotechnologies, all of which offer end-to-end contract manufacturing services encompassing development, drug substance, and drug product.” |
| Supplier | Pfizer (PFE) | “Lastly, organizations such as Pfizer CentreOne and AbbVie Contract Manufacturing, which offer a portfolio of manufacturing services to increase utilization of internal manufacturing capabilities.” |
| Supplier | AbbVie (ABBV) | “Lastly, organizations such as Pfizer CentreOne and AbbVie Contract Manufacturing, which offer a portfolio of manufacturing services to increase utilization of internal manufacturing capabilities.” |
| Partner | Johnson & Johnson (JNJ) | “In July 2020, the Company, through its wholly owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Janssen Agreement with Janssen for large-scale drug substance manufacturing of Johnson & Johnson's investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the "Product").” |
Quoted from the company's 10-K filed Feb 27, 2026.
Companies that name EBS in their SEC reports
| Relationship to EBS | Company | Filing | Sentence |
|---|---|---|---|
| partner | SOLIGENIX, INC. (SNGX) | 10-K Mar 31, 2026 | “We also initiated a development agreement with Emergent BioSolutions, Inc. ("EBS") to implement a commercially viable, scalable production technology for the RiVax® drug substance protein antigen.” |
| partner | Aptevo Therapeutics Inc. (APVO) | 10-K Mar 26, 2026 | “We have financed our operations to date primarily through royalty and purchase agreements with various partners, sale of business products and segments, public offerings of our common stock, loan proceeds, milestone payments, research and development funding from strategic partners, revenue generated from our previously owned commercial products, and funds received at the date of our spin-off from Emergent.” |
EBS company outlook (results filed Aug 5, 2026)
- “(NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026. "Emergent delivered a strong second quarter, significantly exceeding the high end of our guidance range with revenues of $234 million, primarily driven by accelerated MCM/biodefense contract modifications secured with the U.S. government.”
- “The updated ranges for our 2026 forecast reflect this adjustment.”
Quoted word-for-word from the SEC 8-K results press release.
EBS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.39 | $0.35 | −$0.74 | $123.2M | 2 |
| Next quarter (ends Dec 2026) | $-0.08 | $0.28 | −$0.36 | $143.7M | 2 |
| Current fiscal year (ends Dec 2026) | $0.36 | $0.95 | -62.1% | $657.1M | 2 |
| Next fiscal year (ends Dec 2027) | $1.05 | $0.00 | +$1.05 | $703.3M | 1 |
Key Statistics (as of October 29, 2026 at 06:30 UTC)
| Price | USD 7.09 |
|---|---|
| Change | ▲ 6.30% (up) |
| Previous Close | USD 6.67 |
| Open | USD 6.63 |
| Day Range | USD 6.56 – 7.09 |
| 52-Week Range | USD 4.36 – 14.06 |
| Volume | 800,656 shares |
| Market Cap | $363.53M |
| Exchange | NYQ |
Technical Analysis (EBS)
Nexqual's technical model rates EBS "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 06:30 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.68 (neutral) |
| vs SMA50 | Above (USD 6.39) |
| MACD | 0.01 (positive) |
Analyst Ratings (EBS)
Wall Street analysts rate EBS "Hold" based on 3 analysts, with a mean price target of USD 11 (range USD 10–12), per Nexqual as of October 29, 2026 at 06:30 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 11 |
| High Target | USD 12 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 2 / 0 / 1 |
Earnings (EBS)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $123.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.6 vs est 0.11 ▲ beat |
| 2026-03-31 | USD 0.21 vs est -0.25 ▲ beat |
| 2025-12-31 | USD -0.43 vs est 0.11 ▼ miss |
| 2025-09-30 | USD 1.06 vs est -0.12 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:30 UTC.
Financials & Fundamentals (EBS)
| Total Revenue | $770.20M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +66.30% |
| Gross Margin | +50.44% |
| Operating Margin | +28.34% |
| Profit Margin | -22.96% |
| ROE | -40.29% |
| Debt / Equity | 1.72 |
| Current Ratio | 5.42 |
| Total Cash | $139.70M |
| Total Debt | $588.20M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $85.90M (11.2% of revenue) |
Source: Nexqual, October 29, 2026 at 06:30 UTC.
Financial Health Score (EBS)
Nexqual rates Emergent BioSolutions Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:30 UTC.
| Growth | Critical — Revenue -29% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 56%, operating -9% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Weak — $140M cash and investments vs $590M debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $86M (last 4 quarters to Jun 2026, SEC), 11% margin |
| Efficiency | Critical — ROE -52%, ROA -15.8% (last 4 quarters, SEC) |
Ownership (EBS)
| Insider Ownership | +4.21% |
|---|---|
| Institutional Ownership | +90.45% |
| Shares Outstanding | 51.27M |
| Float | 49.05M |
| Short % of Float | +19.19% |
Source: Nexqual, October 29, 2026 at 06:30 UTC.
Leadership (EBS)
Emergent BioSolutions Inc. is led by Joseph C. Papa Jr., M.B.A., R.Ph., CEO, President & Director, per Nexqual as of October 29, 2026 at 06:30 UTC.
| CEO, President & Director | Joseph C. Papa Jr., M.B.A., R.Ph. |
|---|---|
| Executive Vice President of Quality, Ethics & Compliance | Coleen Glessner |
| Senior Vice President of Products Business | Paul A. Williams |
| Vice President of Communications | Assal Hellmer |
| Senior Vice President of Manufacturing & Bioservices | William Hartzel |
Major Backers & Investors (EBS)
Notable institutional backers of Emergent BioSolutions Inc. include American Century Companies Inc, LSV Asset Management, Acadian Asset Management. LLC, according to Nexqual as of October 29, 2026 at 06:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 5.4% |
| LSV Asset Management | 3.31% |
| Acadian Asset Management. LLC | 2.62% |
| Charles Schwab Investment Management, Inc. | 2.34% |
| Oak Hill Advisors, L.P. | 2.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.2% |
| Dimensional Fund Advisors | 6% |
| State Street | 5.71% |
| Vanguard Group | 4.29% |
| Geode Capital | 2.61% |
Source: Nexqual, October 29, 2026 at 06:30 UTC.
From Emergent BioSolutions Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- During 2025, we announced approximately $27 million in incremental sales to supply international customers with five critical MCM products, and we secured $29 million in MCM product orders from an international government partner.
- The mpox indication was approved by the FDA following a supplemental Biological License Application ("sBLA") approval issued in August 2024.
- First, contract manufacturers such as Thermo Fisher Scientific, Lonza, and FUJIFILM Biotechnologies, all of which offer end-to-end contract manufacturing services encompassing development, drug substance, and drug product.
- Our services utilize diverse technology platforms (mammalian, microbial, viral and plasma) from our development and manufacturing facilities to support internal products and enable us to offer unique capabilities to both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations.
Partnerships
- In connection with the divestiture, the Company entered into a Transition Services Agreement with Bavarian Nordic to help support its ongoing operations that was substantially completed in 2024.
- In March 2025, we completed the sale of the Baltimore-Bayview drug substance manufacturing facility to Syngene for approximately $36.5 million at closing, while retaining the right to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be subject to government investigations into compliance with government acquisition regulations.
- Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.
- Our MCM product candidates may be eligible for approval under the FDA's "Animal Rule," under which findings from adequate and well controlled animal efficacy studies may serve as the basis of an approval when it is not feasible or ethical to conduct efficacy trials in humans.
- The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 41.08 | ▲ 0.29% |
| BHC | Bausch Health Companies Inc. | USD 6.92 | ▲ 9.67% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.07 | ▼ 0.81% |
| RGC | Regencell Bioscience Holdings L | USD 7.27 | ▼ 2.55% |
| LQDA | Liquidia Corporation | USD 45.72 | ▲ 0.62% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.77 | ▲ 0.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:30 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt